Introduction {#S5}
============

*Neisseria (N.) gonorrhoeae*, is the world's second most prevalent sexually transmissible bacterial infection.^[@R1]^ However, *N. gonorrhoeae* is a naturally competent organism that can acquire new genes from the microbial environment.^[@R2]^ Those newly acquired genetic variations can render the organism less susceptible, or even resistant, to antimicrobial therapy.^[@R2]^

As the organism has developed resistance to multiple classes of antibiotics such as sulfas, penicillins, tetracyclines, fluoroquinolones and macrolides, the third-generation extended-spectrum cephalosporins, like cefixime, are among the few reliable efficacious treatment options left.^[@R3]^ Cefixime is a highly useful antibiotic used for the treatment of gonorrhoea. *N. gonorrhoeae* remains susceptible to cefixime in most but not all countries.^[@R4]^ Currently, the World Health Organization (WHO) recommends cefixime, in combination with azithromycin, as dual therapy for oropharyngeal, genital and anorectal gonococcal infection.^[@R5]^ In settings where local resistance data confirm cefixime susceptibility, the WHO recommends cefixime in a single dose for genital and anorectal gonococcal infection. In the USA, the Centers for Disease Control and Prevention also recommends cefixime, in combination with azithromycin, as an alternative regimen where ceftriaxone is not available.^[@R6]^ In the UK, oral cefixime in combination with azithromycin is also recommended in penicillin-allergic patients for whom intramuscular injection is contraindicated or refused.^[@R7]^ Cefixime has a serum half-life of 3--4 h in patients with normal renal function, high bioavailability after a single oral dose and is very well tolerated even in penicillin-allergic patients.^[@R6]^ However, in the last two decades, various investigators have reported cases of *N. gonorrhoeae* infection with strains that have decreased susceptibility to cefixime.^[@R8]--[@R30]^ Furthermore, in the past 10 years, cases of *N. gonorrhoeae* treatment failure in patients treated with cefixime have also been reported in Japan,^[@R31]^ Norway,^[@R32]^ UK,^[@R33],[@R34]^ South Africa,^[@R28]^ France,^[@R9]^ Australia^[@R35]^ and Canada.^[@R24]^ Various research teams and governmental institutions have expressed the need for more research on the mechanisms of cefixime resistance and the development of new tools to predict cefixime susceptibility.^[@R36]--[@R38]^

One target protein that is critical for the antimicrobial activity of many β-lactam antibiotics, including cefixime, is the penicillin-binding protein 2 (PBP2), which is a protein essential for the development of bacterial cell walls.^[@R39]^ PBP2 is a transpeptidase encoded by the *penA* gene. Mosaicism of the *penA* gene in *N. gonorrhoeae* was first described by Ameyama *et al*.^[@R40]^ who found that some *penA* nucleotide sequences of *N. gonorrhoeae* contained portions that highly resemble those of other non-pathogenic or commensal Neisseria species, such as *N. perflava*, *N. cinerea*, *N. flavescens* and *N. meningitidis*. *penA* mosaicism, along with other point mutations in *penA*, helps *N. gonorrhoeae* to develop resistance against extended-spectrum cephalosporins like cefixime.^[@R14]--[@R27],[@R41]--[@R43]^

In this review, we describe molecular mechanisms of cefixime-decreased susceptibility in *N. gonorrhoeae*, summarise findings from published reports of various gene mutations contributing to that decreased susceptibility and make suggestions on how to develop a molecular-based cefixime susceptibility assay.

Methods {#S6}
=======

Definition of cefixime-decreased susceptibility {#S7}
-----------------------------------------------

Historically, defining decreased susceptibility or resistance of *N. gonorrhoeae* to cefixime has been challenging due to the scarcity of treatment failure cases.^[@R37]^ The most up-to-date recommendations of antimicrobial minimum inhibitory concentration (MIC) breakpoints by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) in the USA are as follows:

1.  EUCAST: susceptible ≤0.125 μg mL^−1^; resistant \>0.125 μg mL^−1^.^[@R44]^

2.  CLSI: susceptible ≤ 0.25 μg mL^−1^; intermediate: not applicable; resistant: not applicable.^[@R45]^

However, those recommendations might be too liberal when we compare those breakpoints to reported cases of clinical treatment failure. Allen *et al*. reported that the frequency of treatment failure with cefixime for gonococcal infections with an MIC ≥0.12 μg mL^−1^ was 25%, compared with 1.9% among those with an MIC \<0.12 μg mL^−1^.^[@R24]^ For this review, we have described the molecular characteristics of all *N. gonorrhoeae* strains reported, to date, with a MIC ≥0.12 μg mL^−1^ as having a 'decreased susceptibility' to cefixime.

Literature and sequence database review {#S8}
---------------------------------------

One author (X. Deng) searched all articles published on PubMed from 1 January 1995 to 1 November 2018 under the search terms '*Neisseria gonorrhoeae*', 'cefixime' and 'molecular' and reviewed relevant articles cited as references. We identified a total of 74 articles from that search. We included articles that presented epidemiological or experimental evidence of certain molecular alterations contributing to cefixime-decreased susceptibility in *N. gonorrhoeae*; there was a total of 25 reports. All *N. gonorrhoeae* strains with a reported MIC ≥0.12 μg mL^−1^ and specific *penA* alterations associated with cefixime decreased susceptibility were included in [Table 1](#T1){ref-type="table"}, along with their specific MIC plus the time and location of collection.

The nomenclature of *penA* reflects the differences in amino acid sequence rather than nucleotide sequence. Historically, each new amino acid sequence gets a sequential whole number, and is classified into mosaic, semi-mosaic (alterations of either the first or second half of the *penA* gene only^[@R27]^), non-mosaic (point mutations only) and wild-type (*penA* peptide sequence identical to that of the *N. gonorrhoeae* reference strain, M32091^[@R49],[@R50]^). Each different DNA sequence of an existing amino acid sequence gets a decimal number;^[@R27],[@R28]^ for example, the eighth DNA sequence reported for *penA* allele type 2 is assigned allele number *penA*2.008. Our review has exposed conflicting nomenclature for the same *penA* peptide sequence ([Table 2](#T2){ref-type="table"}); likely due to the lack of a single, centralised database requiring new submissions of sequences to be compared with existing entries and subsequently given appropriate designations. We also noticed a general lack of consensus in the standard style of nucleotide or amino acid sequence reporting. Many sequences reported were truncated, leading to incomplete information that hindered data interpretation. We highly recommend future researchers to submit complete gene sequencing data to GenBank (<https://www.ncbi.nlm.nih.gov/genbank/>), which is supported by the National Center for Biotechnology Information (NCBI) and *N. gonorrhoeae* Sequence Typing for Antimicrobial Resistance (NG-STAR, <https://ngstar.canada.ca/>), which is supported by the Government of Canada, for easy reference. To prevent misclassification in this manuscript, we further verified *penA* sequences from each research article against the *penA* profiles in NG-STAR, a centralised, comprehensive and publicly accessible database for standardised characterisation of molecular alterations in *N. gonorrhoeae* worldwide.^[@R27]^ One author (X. Deng) conducted all the multiple peptide sequence alignment using the Multiple Sequence Alignment tool by Clustal Omega (<https://www.ebi.ac.uk/Tools/msa/clustalo/>).

Estimation of assay sensitivity {#S9}
-------------------------------

We proposed a parsimonious group of *penA* amino acid locations to predict decreased susceptibility to cefixime in *N. gonorrhoeae* strains. We estimated the sensitivity of a hypothetical assay for predicting decreased susceptibility using those locations by calculating the number of isolates with genotypic mutations in those locations divided by the number of phenotypically decreased susceptible isolates using the data summarised in [Table 1](#T1){ref-type="table"}.

Results {#S10}
=======

Overview of the molecular mechanisms of cefixime-decreased susceptibility {#S11}
-------------------------------------------------------------------------

[Table 3](#T3){ref-type="table"} shows a list of *penA* types from the NG-STAR database and the presence or absence of amino acid alterations associated with cefixime-decreased susceptibility. Decreased susceptibility to cefixime has been associated with many genetic alterations in the *penA* gene. There is strong laboratory and epidemiological research supporting mosaicism^[@R14],[@R40]^ and other point mutations^[@R19],[@R47],[@R48],[@R51]^ of the *penA* gene as mechanisms for cefixime-decreased susceptibility by means of PBP2 targ*et al*teration. Evidence supporting the importance of alterations in other genes are not as compelling. However, there is evidence that isolates with identical *penA* alleles could have different MIC levels (susceptible with an MIC \<0.125 μg mL^−1^ vs highly resistant with an MIC ≥ 0.5 μg mL^−1^), indicating the involvement of other genes in decreasing susceptibility to cefixime.^[@R27]^ Several candidate genes contributing to cefixime decreased susceptibility include *mtrR*, the transcriptional regulator for the *mtrCDE* efflux pump system;^[@R52]^ *ponA*, encoding for penicillin-binding protein 1 (PBP1);^[@R53]^ *pilQ*, encoding for the type IV pilus secretin;^[@R54]^ and *penB* (alias: *porB1b*), encoding for a major outer membrane protein, *porB*, a porin.^[@R55]^

penA -- penA mosaicism {#S12}
----------------------

Mosaicism in *penA* was found to be the primary determinant of cefixime-decreased susceptibility by many studies.^[@R14]--[@R27],[@R41]--[@R43]^ From an aggregate of 415 *N. gonorrhoeae* isolates with a MIC ≥0.12 μg mL^−1^ from 25 reports representing 22 countries, 83.1% (345 out of 415) were found to have mosaic *penA* genes ([Table 1](#T1){ref-type="table"}). Among all the different mosaic patterns, *penA*10^[@R10],[@R56],[@R57]^ and *penA*34^[@R15],[@R17],[@R21]--[@R23],[@R27],[@R42],[@R56],[@R58]^ were the most frequently reported mosaic *penA* patterns of all isolates with mosaic *penA* gene mutations among *N. gonorrhoeae* strains with reduced cefixime susceptibility \[accounting for 39.1% (135 out of 345) and 49.9% (172 out of 345) respectively\]. While *penA*34 was found worldwide, *penA*10 was mostly found in Asia, and was also associated with resistance to, and treatment failure by, another third-generation cephalosporin, ceftibuten.^[@R59]^

The I312M, V316T, N512Y and G545S amino acid substitutions are frequently seen in mosaic *penA* patterns. Researchers have found that amino acid substitutions, I312M,^[@R19],[@R25]^ V316T/P^[@R19],[@R25],[@R48]^ and G545^[@R19],[@R25],[@R60],[@R61]^ are associated with reduced cefixime susceptibility. However, a gene transformation study by Tomberg *et al*.^[@R51]^ in 2010 showed that when introduced into a wild-type *penA*, I312M, V316T and G545S together only minimally elevated the cefiximeMIC. The reversion of the triple mutation in a cefixime-resistant strain 35/02 (with *penA*10) back into wild-type returned its MIC to that similar to the wild-type *penA* MIC, indicating that those three mutations are important to cefixime resistance only in the context of other mutations found in mosaic *penA*10 alleles.

In the same study by Tomberg *et al*.,^[@R51]^ chimeric *penA* genes were created by replacing sequential portions of *penA*10 with the corresponding regions of a wild-type *penA* gene. Reversion of amino acid regions 309--353 (containing I312M and V316T and 13 other substitutions), 489--528 (containing N512Y and two other mutations) and 528--581 (containing G545S and nine other substitutions), showed significant decrease in MIC. Among the three, the reversion of region 528--581 decreased the MIC to such a significant degree that the chimera could not be selected despite multiple attempts, indicating mutations in this region may be critical factors in influencing cefixime susceptibility. When the G545S substitution was re-introduced to the 528--581-wild-type *penA*10, the resulting strain's cefixime MIC only rose to 0.05 μg mL^−1^, suggesting that other mutations in the 528--581 region were necessary to significantly elevate the cefixime MIC to \>0.125 μg mL^−1^.

The reversion of region 489--528 (containing N512Y and two other mutations) decreased the MIC from \~0.125 to \~0.05 μg mL^−1^. Y512N reversion alone presented a decreased MIC from \~0.125 to \~0.06 μg mL^−1^. Accounting for most of the effect on cefixime resistance by mutations in the 489--528 region, N512Y showed major importance in conferring cefixime resistance in the context of other mosaic changes.

In summary, I312M, V316T, N512Y and G545S were found to be important to cefixime-decreased susceptibility or resistance only in the context of other mutations found in mosaic *penA* alterations. All of them were associated with, but none was necessary or sufficient for, cefixime-decreased susceptibility or resistance.

penA -- non-mosaic penA with point amino acid alterations -- A501 + G542 + P551 {#S13}
-------------------------------------------------------------------------------

Although the *penA*34 mosaicism was present in 98% of all isolates with a MIC ≥0.25 μg mL^−1^ in the study by Grad *et al*. involving more than 1100 *N. gonorrhoeae* isolates collected in the USA, the percentage lowered to 91% when a lower and more clinically relevant MIC breakpoint (0.125 μg mL^−1^) was used.^[@R27]^ That indicates the role of other non-*penA*34 mutations, most notably, other amino acid substitutions in the *penA* gene. In the last decade, more than a dozen cefixime-resistant *N. gonorrhoeae* strains reported in Asia^[@R8],[@R10],[@R14],[@R18]^ and Europe^[@R17]^ were found to have non-mosaic *penA* alleles ([Table 1](#T1){ref-type="table"}). Among reports from Asia, over 20% of *N. gonorrhoeae* strains with decreased susceptibility to cefixime had non-mosaic *penA* mutations. Gene transformation experiments have identified multiple, important amino acid substitutions in non-mosaic *penA* that significantly decrease cefixime susceptibility.^[@R47]^

Three amino acid substitutions, A501S/V/T/P, G542S and P551S/L/P, have been associated with cefixime-decreased susceptibility independent from *penA* mosaicism.^[@R16],[@R21]^ The study by Tomberg *et al*. demonstrated that an independent A501 substitution potentially decreased cefixime susceptibility by increasing the rigidity of the PBP2 active site.^[@R47]^

In [Table 1](#T1){ref-type="table"}, we have summarised the cefixime-decreased susceptible related *penA* amino acid alterations in all *N. gonorrhoeae* strains with a cefixime MIC 0.12 μg mL^−1^. One important finding is that 68 out of 70 (97.1%) non-mosaic *penA* strains with reduced susceptibility to cefixime have a point mutation in at least one of the three codons, A501, G542 and P551. Additionally, decreased susceptible *N. gonorrhoeae* strains with non-mosaic *penA* have mostly been reported in Asia and Europe.

In [Figure 1](#F1){ref-type="fig"}, we have summarised the MIC levels of all *N. gonorrhoeae* strains with cefixime MIC ≥ 0.12 μg mL^−1^ by different combinations of decreased susceptible-related *penA* amino acid alterations (*n* = 240). Strains lacking a specific cefixime MIC value or *penA* alteration records (*n* = 175) were excluded.

mtrR {#S14}
----

*mtrR* is a repressor gene that regulates the expression of the *mtrCDE* efflux pump system, an important mechanism in transporting antimicrobial agents out of the bacterial cell.^[@R52]^ Changes in the promoter or coding sequence of the *mtrR* gene can potentially decrease antimicrobial susceptibility by increased efflux.^[@R62]^ There are conflicting reports on the importance of the *mtrR* gene in cefixime-decreased susceptibility. Mutations frequently found in strains with cefixime-decreased susceptibility include a −35A deletion in the promoter region,^[@R13],[@R22]^ plus A39T and G45D^[@R22]^ in the coding region. We did not find gene transformation studies that looked into *mtrR* alterations' contribution to cefixime resistance independent from *penA* changes. Nonetheless, other studies report that mutations in the *mtrR* gene have little or no association with cefixime susceptibility.^[@R58],[@R62]^

penB (porB1b) {#S15}
-------------

*penB*, also known as *porB1b*, encodes for an outer membrane porin and is thought to increase penicillin resistance by changing the bacterial membrane permeability to certain antibiotics when *penA* and *mtrR* mutations are also present, although its role in cefixime resistance is unclear.^[@R58],[@R63]^ Alterations found in strains with cefixime-decreased susceptibility include G120K and A121N/D substitutions.^[@R42]^ While the study by Grad *et al*. in the USA suggested no correlation between cefixime-decreased susceptibility and G120K or G120D/A121D, the lack of G120K *and* A121N mutations strongly predicted susceptibility.^[@R27]^

Two other mutations in the *penB* gene commonly found in cefixime-decreased susceptible strains are G101K/D and A102D/N/S. Combinations of mutations at those two sites were found in all 48 strains with a cefixime MIC \>0.125 μg mL^−1^ out of the total 329 *N. gonorrhoeae* strains in the Serra-Pladevall *et al*. study^[@R17],[@R22]^ and among all 127 strains with a cefixime MIC ≥0.125 μg mL^−1^ out of the total 194 *N. gonorrhoeae* strains in the study by Jeverica *et al*.^[@R22]^

We have found no evidence that alterations in the *penB* gene alone can confer decreased susceptibility to cefixime.

ponA {#S16}
----

*ponA* encodes for penicillin-binding protein 1 (PBP1), an additional cell wall protein important in β-lactam antibiotic antimicrobial activity. Alterations in the *ponA* gene were associated with penicillin resistance by PBP1 target mutation, although its role in cefixime-decreased susceptibility is unclear.^[@R19],[@R37],[@R58]^ One mutation, L421P,^[@R17],[@R42],[@R64]^ was frequently found in cefixime-decreased susceptible strains, but a gene transformation study showed that a *ponA* L421P substitution does not contribute additional decreased susceptibility to cefixime without a mosaic *penA* gene.^[@R62]^

pilQ {#S17}
----

*pilQ* encodes for a type IV pili secretin.^[@R54]^ Mutations in the *pilQ* gene are thought to increase penicillin resistance by changing the bacterial membrane permeability when *penA*, *mtrR* or *penB* mutations are also present, although its role in cefixime resistance is also unclear.^[@R58],[@R63]^

While the study by Whiley *et al*.^[@R63]^ concluded that changes in the *pilQ* gene are unlikely associated with cefixime-decreased susceptibility, the study by Grad *et al*.^[@R27]^ found that a 176--183 deletion (vs full length), N341S, D526N/G or N648S each strongly predicted *N. gonorrhoeae* susceptibility to cefixime. Notably, among those four mutations, N648S was the only mutation that was found to be relatively common (in 23.7% of all isolates compared with ≤10% for any of the other three).

Discussion {#S18}
==========

Prediction of cefixime susceptibility using molecular markers {#S19}
-------------------------------------------------------------

Antimicrobial stewardship is important in the control of antimicrobial resistance in infectious diseases.^[@R65]^ Antimicrobial use results in selective pressure, favouring the development of resistant organisms.^[@R65]^ Therefore, the use of molecular assays to predict antimicrobial susceptibility at the time of treatment allows for targeted therapy, enabling the use of antimicrobials shown to be highly effective and rapidly bactericidal, as well as the use of older medications previously deemed non-effective because of prevalent resistance.^[@R66],[@R67]^ Such molecular assays to predict susceptibility could be a valuable complement to antimicrobial stewardship and novel drug development in slowing the emergence of antimicrobial resistance.^[@R38]^

Previously, we developed a polymerase chain reaction-based assay using high resolution melt analysis to predict *N. gonorrhoeae* susceptibility to ceftriaxone and cefixime by targeting the *penA*34 type.^[@R68]^ While that assay showed greater than 98% sensitivity in predicting cefixime-decreased susceptibility in North America, where the *penA*34 is the most common *penA* type,^[@R27],[@R50]^ the assay is limited by its inability to identify cefixime-decreased susceptibility as a result of *N. gonorrhoeae* strains with non-mosaic *penA* or other non-34 mosaic *penA* patterns. As *N. gonorrhoeae* strains with various non-34 *penA* types account for many of the cefixime-resistant strains reported in Asia and Europe, it is likely only a matter of time for such strains to emerge in other parts of the world, including in the USA.

Additional amino acid alterations should be considered when developing a molecular assay to predict cefixime susceptibility, especially when a lower and more clinically relevant MIC breakpoint (\<0.12 μg mL^−1^) is used.

For the *penA* gene, either of the following patterns of alterations could lead to elevated cefixime MIC levels: (1) mosaic *penA* types with characteristic polymorphisms I312M, V316T, N512Y, G545S; or (2) non-mosaic *penA* types with mutations at any combinations of the three amino acid positions: A501, G542 or P551. A multiple peptide sequence alignment showed that a wild-type sequence of amino acid region 375--377 can reliably distinguish 32 out of 33 types of wild-type and non-mosaic *penA* types (with the only exception being the non-mosaic *penA*49 type possessing a A377V substitution) from all 21 reported mosaic *penA* types (data not shown). Other researchers have targeted other regions or used the characteristic amino acid polymorphisms in mosaic *penA* types such as I312M, V316T and G545S.^[@R19],[@R69]^

Non-mosaic *penA* types with critical point mutations can be identified by the absence of changes at amino acid region 375--377, and the presence of one of the three critical point mutations A501, G542 or P551. A molecular assay that detects any *penA* alterations at amino acid positions 375--377, 501, 542 or 551 would be the most parsimonious assay to predict decreased susceptibility to cefixime. That modified assay would be more effective in predicting cefixime susceptibility than the assay we previously developed,^[@R68]^ with greater sensitivity for diverse international isolates. Based on the molecular characteristics of all reported strains with decreased susceptibility to cefixime as recorded in [Table 1](#T1){ref-type="table"}, the estimated sensitivity for the proposed assay would be 99.5% (413 out of 415).

Other genes, such as *mtrR*, *ponA*, *penB* and *pilQ*, have a less clear role in cefixime resistance and seem to further increase cefixime MIC values only when *penA* alterations are present. Although certain alterations in these genes were found to be highly associated with full susceptibility as mentioned above, detecting these changes appears to be unnecessary as *N. gonorrhoeae* will constantly undergo selection by antimicrobial agents and gradually gain mutations that eventually lead to cefixime resistance.

Conclusion {#S20}
==========

Because of the continued challenge in treating antimicrobial-resistant *N. gonorrhoeae* infections, there have been many reports published regarding the genetic alterations associated with decreased susceptibility to third-generation cephalosporins. Researchers have provided epidemiological and molecular evidence that alterations in the *penA* gene are the primary determinants of cefixime-decreased susceptibility, while other genes in the presence of an altered *penA* gene further contribute in reducing cefixime susceptibility but are neither necessary nor sufficient in independently conferring decreased susceptibility. Based on those data, we proposed the optimal targets for novel molecular assays aiming to predict *N. gonorrhoeae* susceptibility to cefixime.
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###### Summary of *penA* alterations in reported gonococcal strains with a cefixime minimum inhibitory concentration of *≥*0.12 μg mL^−1[A](#TFN1){ref-type="table-fn"}^

CFX, cefixime; WHO, World Health Organization

  Reference   Country of collection           Year             Frequency                                 CFX MIC (μg mL^−1^)                     *penA* type                             *penA* mosaicism   Amino acid alteration at numbered position                                                                                                     
  ----------- ------------------------------- ---------------- ----------------------------------------- --------------------------------------- --------------------------------------- ------------------ -------------------------------------------- --- --- --- --- ------------------------------------ --- ------------------------------------ --- ---
  ^[@R14]^    Japan                           2001             8/55^[B](#TFN2){ref-type="table-fn"}^     0.125                                   1\~9^[C](#TFN3){ref-type="table-fn"}^   non-mosaic                                                              x       V^[D](#TFN4){ref-type="table-fn"}^       S^[E](#TFN5){ref-type="table-fn"}^       
  ^[@R15]^    Argentina                       2009--13         1/1987                                    0.125                                   5                                       non-mosaic                                                              x                                                S                                        
  ^[@R8]^     Vietnam                         2011             1/108                                     0.125                                   5+^[F](#TFN6){ref-type="table-fn"}^     non-mosaic                                                              x       V                                        S                                        
  ^[@R16]^    Canada                          2001--10         1/155                                     0.5                                     5+                                      non-mosaic                                                              x                                                S                                        
  ^[@R9]^     (WHO reference strain L)                         0.25                                      7                                       non-mosaic                                                                                                  x       S                                        S                                        S   
  ^[@R15]^    Argentina                       2009--13         1/1987                                    0.125                                   9                                       non-mosaic                                                              x                                                                                         L
                                                               1/1987                                    0.5                                     12                                      non-mosaic                                                              x                                                                                         S
  ^[@R16]^    Canada                          2001--10         3/155                                     ≥0.125                                  12+                                     non-mosaic                                                              x                                                                                         S
  ^[@R17]^    Spain                           2013             13/329                                    ≥0.125                                  12+^[G](#TFN7){ref-type="table-fn"}^    non-mosaic                                                              x       T                                                                                 L
                                                               2/329                                                                                                                                                                                             x                                                                                         
                                                               2/329                                                                                                                                                                                             x                                                                                         L
                                                               1/329                                                                                                                                                                                             x                                                S                                        
                                                               1/329                                                                                                                                                                                             x       S                                        S                                        
  ^[@R18]^    China                           2014--15         3/126                                     0.125                                   13                                      non-mosaic                                                              x       V                                                                                 S
  ^[@R15]^    Argentina                       2009--13         1/1987                                    0.125                                   13                                      non-mosaic                                                              x       V                                                                                 S
  ^[@R10]^    Korea                           2011--2013       6/210                                     0.12                                    13                                      non-mosaic                                                              x       V                                                                                 S
                                                               13/210                                    0.25                                                                                                                                                    x       V                                                                                 S
                                                               2/210                                     0.5                                                                                                                                                     x       V                                                                                 S
  ^[@R18]^    China                           2014--15         1/126                                     0.25                                    13+                                     non-mosaic                                                              x       V                                    Y                                            S
  ^[@R16]^    Canada                          2001--10         1/155                                     0.125                                   13+                                     non-mosaic                                                              x       V                                                                                 S
  ^[@R8]^     Vietnam                         2011             1/108                                     0.25                                    18                                      non-mosaic                                                              x       T                                        S                                        
                                                               2/108                                     0.125                                                                                                                                                   x       T                                        S                                        
                                                               1/108                                     0.125                                                                                                                                                   x       T                                        S                                        
                                                               2/108                                     0.125                                                                                                                                                   x       T                                        S                                        
                                                               1/108                                     0.125                                                                                                                                                   x       T                                        S                                        
  ^[@R18]^    China                           2014--15         1/126                                     0.125                                   21                                      non-mosaic                                                              x       V                                                                                 
  ^[@R19]^    Japan                           2002             20/58                                     0.25                                    10                                      mosaic                                                          M   T                                                Y                                        S   
                                                               4/58                                      0.5                                                                                                                                             M   T                                                Y                                        S   
  ^[@R14]^    Japan                           2001             37/55^[B](#TFN2){ref-type="table-fn"}^    ≥ 0.5                                   10                                      mosaic                                                          M   T                                                Y                                        S   
                                                               8/55^[B](#TFN2){ref-type="table-fn"}^     0.25                                                                                                                                            M   T                                                Y                                        S   
                                                               2/55^[B](#TFN2){ref-type="table-fn"}^     0.125                                                                                                                                           M   T                                                Y                                        S   
  ^[@R18]^    China                           2014--15         3/126                                     0.25                                    10^[H](#TFN8){ref-type="table-fn"}^     mosaic                                                          M   T                                                Y                                        S   
  ^[@R15]^    Argentina                       2009--13         3/1987                                    0.5                                     10                                      mosaic                                                          M   T                                                Y                                        S   
  ^[@R10]^    Korea                           2011--2013       3/210                                     0.25                                    10                                      mosaic                                                          M   T                                                Y                                        S   
                                                               1/210                                     0.5                                                                                                                                             M   T                                                Y                                        S   
  ^[@R46]^    (Modified laboratory strain)                     \>0.25                                    10                                      mosaic                                                     M                                            T               Y                                        S                                        
  ^[@R9]^     (WHO reference strain K)                         0.5                                       10                                      mosaic                                                     M                                            T               Y                                        S                                        
              (Modified laboratory strain)                     0.5                                       10^[I](#TFN9){ref-type="table-fn"}^     mosaic                                                     M                                            T               Y                                        S                                        
  ^[@R16]^    Canada                          2001--10         12/155                                    ≥ 0.25                                  10                                      mosaic                                                          M   T                                                Y                                        S   
  ^[@R20]^    Canada                          2008             8/149                                     0.25                                    10^[H](#TFN8){ref-type="table-fn"}^     mosaic                                                          M   T                                                Y                                        S   
  ^[@R11]^    Japan                           1998--2007       25/36^[J](#TFN10){ref-type="table-fn"}^   0.25                                    10                                      mosaic                                                          M   T                                                Y                                        S   
                                              2003--04         5/36^[J](#TFN10){ref-type="table-fn"}^    0.5                                                                                                                                             M   T                                                Y                                        S   
  ^[@R19]^    Japan                           2002             4/58                                      0.12                                    10                                      mosaic                                                          M   T                                                Y                                        S   
  ^[@R47]^    (Modified laboratory strains)                    0.25                                      10+^[K](#TFN11){ref-type="table-fn"}^   mosaic                                                     M                                            T           S   Y                                        S                                        
                                                                                                         0.25                                                                                                                                            M   T           T                                    Y                                        S   
                                                                                                         0.25                                                                                                                                            M   T           V                                    Y                                        S   
                                                                                                         0.5                                                                                                                                             M   T           R                                    Y                                        S   
                                                                                                         0.5                                                                                                                                             M   T           P                                    Y                                        S   
  ^[@R48]^    (Modified laboratory strains)                    0.125                                     10+^[K](#TFN11){ref-type="table-fn"}^   mosaic                                                     M                                            T               Y                                        S                                        
                                                                                                         \>0.125                                                                                            V                                            M   T                                                Y                                        S   
                                                                                                         0.25                                                                                                                                            M   P                                                Y                                        S   
                                                                                                         0.25                                                                                               V                                            M   T       S                                        Y                                        S   
                                                                                                         \>0.5                                                                                              V                                            M   P                                                Y                                        S   
                                                                                                         \>1.5                                                                                              V                                            M   P       S                                        Y                                        S   
  ^[@R11]^    Japan                           2003             1/36^[J](#TFN10){ref-type="table-fn"}^    0.5                                     30                                      mosaic                                                          M   T       V                                        Y                                        S   
                                              2003             1/36^[J](#TFN10){ref-type="table-fn"}^    1                                                                                                                                               M   T       V                                        Y                                        S   
                                              2001             1/36^[J](#TFN10){ref-type="table-fn"}^    0.25                                    31                                      mosaic                                                          M   T                                                Y                                        S   
                                              2005             1/36^[J](#TFN10){ref-type="table-fn"}^    0.25                                    32                                      mosaic                                                          M   T                                                Y                                        S   
                                              2005             1/36^[J](#TFN10){ref-type="table-fn"}^    0.5                                                                                                                                             M   T                                                Y                                        S   
  ^[@R15]^    Argentina                       2009--13         15/1987                                   0.25                                    34                                      mosaic                                                          M   T                                                Y                                        S   
                                                               20/1987                                   0.125                                                                                                                                           M   T                                                Y                                        S   
  ^[@R21]^    Italy                           2011--2014       45/50^[B](#TFN2){ref-type="table-fn"}^    \>0.125                                 34                                      mosaic                                                          M   T                                                Y                                        S   
  ^[@R17]^    Spain                           2013             28/329                                    ≥0.125                                  34                                      mosaic                                                          M   T                                                Y                                        S   
  ^[@R12]^    Japan                           2011             Case report                               0.125                                   34                                      mosaic                                                          M   T                                                Y                                        S   
  ^[@R13]^    Ireland                         2014--16         10/608                                    0.125                                   34                                      mosaic                                                          M   T                                                Y                                        S   
  ^[@R22]^    Slovenia                        2006--2012       28/194                                    0.125                                   34                                      mosaic                                                          M   T                                                Y                                        S   
  ^[@R23]^    Switzerland                     2010             1/34                                      0.19                                    34                                      mosaic                                                          M   T                                                Y                                        S   
                                              2011             1/34                                      0.19                                                                                                                                            M   T                                                Y                                        S   
                                                               1/34                                      0.125                                                                                                                                           M   T                                                Y                                        S   
                                                               1/34                                      0.125                                                                                                                                           M   T                                                Y                                        S   
  ^[@R46]^    (Modified laboratory strains)                    \>0.125                                   34                                      mosaic                                                     M                                            T               Y                                        S                                        
  ^[@R28]^    South Africa                    2012             Case report                               0.25                                    34                                      mosaic                                                          M   T                                                Y                                        S   
  ^[@R24]^    Canada                          2010--11         7/9^[L](#TFN12){ref-type="table-fn"}^     0.12                                    34                                      mosaic                                                          M   T                                                Y                                        S   
  ^[@R20]^    Canada                          2008             1/149                                     0.125                                   34                                      mosaic                                                          M   T                                                Y                                        S   
                                                               1/149                                     0.25                                                                                                                                            M   T                                                Y                                        S   
  ^[@R25]^    USA                             2008             Case report                               0.25                                    34                                      mosaic                                                          M   T                                                Y                                        S   
                                                                                                         0.125                                                                                                                                           M   T                                                Y                                        S   
  ^[@R21]^    Italy                           2011--2014       1/50^[B](#TFN2){ref-type="table-fn"}^     \>0.125                                 34+                                     mosaic                                                          M   T           V                                    Y                                        S   
  ^[@R29]^    Republic of Georgia             Did not report   Case report                               0.5                                     34+                                     mosaic                                                          M   T                                                Y                                        S   
  ^[@R12]^    Japan                           2012             Case report                               0.125                                   34+                                     mosaic                                                          M   T           V                                    Y                                        S   
  ^[@R46]^    (Modified laboratory strains)                    \>0.35                                    34+                                     mosaic                                                     M                                            T               Y                                        S                                    S   
                                                                                                         \>0.5                                                                                                                                           M   T           S                                    Y                                        S   
  ^[@R26]^    Spain                           Did not report   Case report                               1.5                                     34+                                     mosaic                                                          M   T           p                                    Y                                        S   
  ^[@R12]^    Japan                           2011             Case report                               0.25                                    34+                                     mosaic                                                          M   T                                                Y                                        S   S
                                                                                                         0.25                                                                                                                                            M   T                                                Y                                        S   S
                                                                                                         0.25                                                                                                                                            M   T                                                Y                                        S   S
                                              2012                                                       0.25                                                                                                                                            M   T                                                Y                                        S   S
                                                                                                         0.25                                                                                                                                            M   T                                                Y                                        S   S
  ^[@R20]^    Canada                          2008             2/149                                     0.25                                    35^[M](#TFN13){ref-type="table-fn"}^    mosaic                                                          M   T                                                                                             
  ^[@R30]^    Japan                           2009             Case report                               4                                       37                                      mosaic             V                                            M   P       S                                        Y                                        S   
  ^[@R48]^    (Modified laboratory strains)                    1.6                                       37^[N](#TFN14){ref-type="table-fn"}^    mosaic                                  V                  M                                            P       S       Y                                        S                                        
  ^[@R30]^    France                          2010             Case report                               2                                       42                                      mosaic                                                          M   T           P                                    Y                                        S   
  ^[@R9]^     France                          2010             Case report                               4                                       42^[O](#TFN15){ref-type="table-fn"}^    mosaic                                                          M   T           P                                    Y                                        S   
  ^[@R30]^    Japan                           2015             Case report                               1                                       60                                      mosaic             V                                            M   T       S                                        Y                                        S   
              Japan                           2014                                                       1                                                                                                  V                                            M   T       S                                        Y                                        S   
              Denmark                         2017                                                       1                                                                                                  V                                            M   T       S                                        Y                                        S   
              Canada                          2017                                                       2                                                                                                  V                                            M   T       S                                        Y                                        S   
              Australia                       2013                                                       2                                       64                                      mosaic             V                                            M   T       S                                        Y                                        S   
  ^[@R21]^    Italy                           2011--2014       4/50^[B](#TFN2){ref-type="table-fn"}^     \>0.125                                 not reported                            mosaic             (Amino acid sequence not reported)                                                                                                             
  ^[@R16]^    Canada                          2001--10         17/155                                    ≥0.125                                  not reported                            mosaic                                                          M   T                                                Y                                        S   
                                                               1/155                                     0.25                                                                                                                                            M   T                                                                                             
  ^[@R11]^    Japan                           2003             1/36^[J](#TFN10){ref-type="table-fn"}^    0.5                                     not reported                            mosaic                                                          M   T                                                Y                                        S   

An 'x' indicates the presence of the amino acid alteration indicated in the header row. Other one-letter abbreviations indicate the substitution into the corresponding amino acid.

Among isolates with a cefixime MIC ≥ 0.125 μg mL^−1^.

In the manuscript, the authors reported the MIC values for a group of isolates with decreased susceptibility to cefixime with *penA* type 1\~9.

A501V mutation present only in *penA* 7 and 8; other *penA* types are wild-type at the 501 position.

G542S mutation present only in *penA* 4, 5, 7, 8; other *penA* types are wild-type at the 542 position.

In this entry and hereafter, '+' in the '*penA* type' column indicates that researchers reported the isolate having a *penA* sequence closely resembling the reported type.

In the manuscript, the authors reported the *penA* type as closely resembling *penA* 36.

In the manuscript, the authors reported the *penA* type as *penA* 35.

In the manuscript, the authors reported the *penA* type as *penA* 28.

Among isolates with a cefixime MIC ≥0.25 μg mL^−1^.

In the manuscript, the authors reported the *penA* type as closely resembling *penA* 35.

Among isolates that failed clinical treatment.

In the manuscript, the authors reported the *penA* type as *penA* 38.

In the manuscript, the authors reported the *penA* type as *penA* 41.

In the manuscript, the authors reported the *penA* type as *penA* 51.

###### *penA* gene types with conflicting nomenclature

NG- STAR, *Neisseria gonorrhoeae* sequence typing for antimicrobial resistance

  Reference strain   *penA* type by NG-STAR   *penA* type reported in literature
  ------------------ ------------------------ --------------------------------------------------------------------------------------------
  35/02              10                       mosaic-1 by Takahata *et al*.^[@R19]^
                                              28 by Unemo *et al*.^[@R9]^
                                              35 by Allen *et al*.^[@R20]^ Tomberg *et al*.^[@R47],[@R48],[@R51]^ Jiang *et al*.^[@R18]^
  F98                42                       51 by Unemo *et al*.^[@R9]^
                                              42 by Lahra *et al*.^[@R30]^
  H041               37                       50 by Unemo *et al*.^[@R9]^
                                              41 by Tomberg *et al*.^[@R48]^
                                              37 by Lahra *et al*.^[@R30]^
  FA6140             12                       36 by Allen *et al*.^[@R20]^ Serra-Pladevall *et al*.^[@R17]^
  /                  35                       38 by Allen *et al*.^[@R20]^ Martin *et al*.^[@R16]^

###### *penA* types: mosaicism and amino acid alterations associated with cefixime-decreased susceptible *Neisseria gonorrhoeae* infections

The one-letter abbreviation of amino acid indicates the substitution of the amino acid described in the header row. The lack of a one-letter abbreviation indicates that the position contains the wild-type amino acid. The x indicates the insertion of an aspartate at amino acid 345 position.

  *penA* type     Mosaicism     Amino acid alteration at number position                                   
  --------------- ------------- ------------------------------------------ --- --- --- --- --- --- --- --- ---
  0 (Wild-type)   Non-mosaic                                                                               
  1               Non-mosaic                                                       x                       
  2               Non-mosaic                                                       x                       
  3               Non-mosaic                                                       x                       
  4               Non-mosaic                                                       x               S       
  5               Non-mosaic                                                       x               S       
  7               Non-mosaic                                                       x       S       S       
  9               Non-mosaic                                                       x                       L
  10              Mosaic                                                   M   T               Y       S   
  11              Non-mosaic                                                       x       V               L
  12              Non-mosaic                                                       x                       S
  13              Non-mosaic                                                       x       V               S
  14              Non-mosaic                                                       x                       
  15              Non-mosaic                                                                               
  17              Non-mosaic                                                       x       V       S       
  18              Non-mosaic                                                       x       T       S       
  19              Non-mosaic                                                       x                       
  21              Non-mosaic                                                       x       V               
  22              Non-mosaic                                                       x                       
  26              Mosaic                                                   M   T               Y       S   
  27              Mosaic                                                   M   T               Y       S   
  30              Mosaic                                                   M   T       V       Y       S   
  31              Mosaic                                                   M   T               Y       S   
  32              Mosaic                                                   M   T               Y       S   
  34              Mosaic                                                   M   T               Y       S   
  35              Mosaic                                                   M   T                           
  37              Mosaic        V                                          M   P       S       Y       S   
  38              Mosaic                                                                                   
  39              Semi-mosaic                                                      x                       
  40              Non-mosaic                                                       x                       
  41              Non-mosaic                                                       x               S       
  42              Mosaic                                                   M   T           P   Y       S   
  43              Non-mosaic                                                       x       V               
  44              Non-mosaic                                                       x       T               L
  45              Non-mosaic                                                                               
  46              Non-mosaic                                                       x                       
  47              Semi-mosaic                                              M   T                           
  48              Non-mosaic                                                       x                       
  49              Non-mosaic                                                       x       T               
  50              Non-mosaic                                                       x                       A
  51              Mosaic                                                   M   T               Y       S   
  52              Mosaic                                                   M   T               Y       S   
  53              Mosaic                                                       T               Y       S   A
  54              Non-mosaic                                                       x       V               A
  55              Mosaic                                                   M   T               Y       S   
  56              Non-mosaic                                                       x       V               G
  57              Non-mosaic                                                       x       V               A
  58              Mosaic                                                                       Y       S   A
  59              Mosaic                                                               S       Y       S   
  60              Mosaic        V                                          M   T       S       Y       S   
  61              Non-mosaic                                                       x                       L
  62              Mosaic                                                                       Y           
  63              Mosaic                                                   M   T                           
  64              Mosaic        V                                          M   T       S       Y       S   
